CytomX Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Masked biologics technology enables targeting of challenging cancer antigens, with lead ADC showing strong efficacy and improved tolerability in late-line CRC. Dose optimization and combination studies are advancing, with expansion into other GI cancers and a masked cytokine program in melanoma. Cash runway extends into 2028.
-
The conference highlighted strong clinical progress for the lead EpCAM-targeting ADC in late-line colorectal cancer, with robust efficacy, manageable safety, and a clear regulatory path. Expansion into combinations and other GI tumors, plus a promising masked interferon program, positions the pipeline for significant near-term milestones.
-
Varseta-M, a first-in-class EpCAM-targeting ADC, is advancing rapidly in late-line colorectal cancer with Fast Track FDA status, promising efficacy, and a favorable safety profile. Combination and expansion studies are underway, while CX-801, a masked interferon alfa-2b, is progressing in late-line melanoma with encouraging early biomarker data.
-
Varseta-M's development in CRC and other GI cancers advanced with strong clinical and operational progress, while financials reflect a robust cash position and increased R&D investment. Key milestones include a major Regeneron collaboration expansion and new executive hires.
-
The Probody platform enables tumor-selective biologics, with Varseta-M showing strong efficacy and safety in late-line CRC and plans for expansion into earlier lines and other tumors. The Regeneron partnership and CX-801 program further broaden the pipeline and funding base.
-
The company highlighted major progress in its Probody platform and expanded its Regeneron collaboration, securing significant funding. Varseta-M demonstrated strong efficacy and manageable safety in late-line CRC, with pivotal trials and combination studies planned.
-
Strong clinical progress for Varseta-M in late-line CRC, robust cash position, and focused capital allocation support advancement into pivotal studies. Next major data update expected in the second half of 2026, with expansion into new indications and combinations underway.
-
Masked ADC technology is showing promising early results in late-line metastatic CRC, with a 28% response rate and manageable safety profile. Dose expansion and combination studies are underway, with a registrational study targeted for 2027.
-
The conference highlighted a robust oncology pipeline with Vaseta M showing strong efficacy and safety in late-line colorectal cancer and plans for expansion into earlier lines and other tumors. CX801 demonstrated promising immune activation in melanoma, with combination data expected by end of 2026.
Fiscal Year 2025
-
Varseta-M showed strong efficacy and improved safety in late-line CRC, with ORR up to 32% and median PFS over 7 months. Dose optimization and dual prophylaxis reduced grade 3 diarrhea to 10%. Registrational studies and expansion into new indications are planned.
-
Probody masking technology showed strong clinical validation in 2025, with CX-2051 achieving notable efficacy and safety in late-stage colorectal cancer and expansion plans underway. CX801 and CX908 advance the pipeline, supported by robust cash reserves and active partnerships.
-
Phase 1 data for a masked anti-EpCAM ADC in late-stage colorectal cancer showed a 28% response rate and 94% disease control, with expansion to 100 patients and a major update planned for Q1 2026. Additional studies in other solid tumors and a masked interferon alpha program are advancing.
-
The conference highlighted significant progress for the Probody platform, with CX-2051 showing strong efficacy and safety in late-line CRC. Enrollment is expanding to support a robust phase one data package for FDA discussions in 2026, backed by solid financials.
-
Lead candidate CX-2051 showed strong efficacy and safety in late-line CRC, with a 28% response rate and 5.8-month PFS, while CX-801 advanced in melanoma. Cash reserves of $143.6M support operations into 2027, with key data updates and new studies planned for 2026.
-
The conference highlighted strong early clinical results for a masked ADC in late-line colorectal cancer, with robust efficacy and a favorable safety profile. Expansion cohorts are fully enrolled, with a major data update expected in Q1 2026, and plans for broader development and strategic partnerships underway.
-
The conference highlighted advances in masked antibody and cytokine therapies for oncology, with CX2051 showing strong early efficacy and safety in late-line colorectal cancer and plans for registrational studies in 2026. CX801, a masked Interferon, is progressing in melanoma with combination trials underway.
-
CX-2051 EpCAM ADC demonstrated strong efficacy and manageable safety in late-line CRC, with a robust expansion phase and next data update expected in Q1 2026. The platform's versatility extends to T-cell engagers and cytokines, while a solid cash position supports advancement toward registrational studies.
-
Strong phase I results for CX-2051 in late-line CRC and a solid financial position highlight the quarter, with expanded studies and key data readouts expected in 2026. CX-801 advances in melanoma, and partnerships continue to support growth.
-
Promising phase I data for CX-2051 in metastatic CRC showed strong efficacy and safety, with expansion cohorts underway and a pivotal data update expected in Q1 2026. The company is well funded, advancing its pipeline, and exploring both independent and partnered growth strategies.
-
Positive interim phase 1 data for CX-2051 in late-line metastatic colorectal cancer showed a 28% response rate, 94% disease control, and favorable safety, supported by $100M in new financing. Plans include expanding trials and moving into phase 2 in 2026.
-
The company highlighted progress on its Probody platform, advancing two clinical programs—CX-2051 for colorectal cancer and CX-801 for melanoma—both on track for key data readouts in 2024. Strong financials and major pharma partnerships support a robust pipeline and expansion plans.
-
The conference highlighted progress in three clinical oncology programs leveraging antibody masking to improve safety and efficacy. Key milestones include initial phase 1a data for CX-2051 in CRC and translational data for CX-801 in melanoma in 2024, with strong financial runway and major partnerships.
Fiscal Year 2024
-
Advanced CX-2051 and CX-801 into the clinic, prioritized these programs, and extended cash runway into Q2 2026. Revenue rose to $138.1M in 2024, driven by collaborations, while initial clinical data for both lead assets is expected in 2025.
-
The conference highlighted advances in conditional antibody masking, with three clinical programs progressing, including CX-904 and CX-2051. Key milestones and initial clinical data for these programs are anticipated in 2025, supporting broader industry validation.
-
Advanced three clinical programs with strong progress in dose escalation and safety across lead assets. Revenue and R&D spending increased year-over-year, with a cash runway through 2025. Multiple clinical data readouts are expected in 2025, supporting value creation and later-stage development.
-
Significant progress was highlighted across three clinical-stage oncology programs, with early efficacy and safety data for the lead T cell engager, CX-904, and strategic partnerships supporting a robust pipeline. Key data updates are expected by year-end and into 2025.
-
The company showcased a robust oncology pipeline with three lead programs advancing in the clinic, highlighted by strong safety and early efficacy signals for CX-904 and promising preclinical and clinical progress for CX-2051 and CX-801. Strategic collaborations and a solid cash position support continued growth.
-
Advanced clinical pipeline with positive phase 1A data for CX-904, especially in pancreatic cancer, and ongoing phase 1 studies for CX-2051 and CX-801. Q2 2024 revenue rose to $25.1M, with $137M in cash expected to fund operations through 2025.
-
The panel highlighted strong progress in tumor-targeted therapies, with CX-904 showing promising safety and efficacy in early trials, especially in pancreatic cancer. Strategic partnerships, robust financials, and a broad pipeline position the company for significant milestones in the next year.
-
The platform is advancing three clinical programs, with CX-904 showing strong safety and efficacy signals in pancreatic cancer and a focus on further enrollment in select tumor types. Strategic partnerships, including with Amgen and Merck, support ongoing development, and the company is well-funded through 2025.